Moreover, melanoma cells made resistant to the BRAF inhibitor vemurafinib, which acts upstream of MEK activation and signalling, exhibited activated SRC signalling in vitro and in vivo, and exhibited sensitivity to SRC inhibition by both dasatinib and saracatinib [49]. The gene discussed is BRAF; the disease is melanoma.